Endoscopic ultrasound as a predictor of pathologic complete response in rectal cancercer

Melissa Jiménez-Morales, Juan Octavio Alonso-Lárraga, José Guillermo De La Mora-Levy, Julio C Sánchez-del Monte, María del Carmen Manzano-Robleda, Armando Alonso-Martínez, Flora M Oña-Ortiz, Mauro E Ramírez-Solís, Angélica Hernández-Guerrero

Article ID: 1747
Vol 5, Issue 1, 2022

VIEWS - 461 (Abstract) 261 (PDF)


The possibility of preoperative prediction of pathologic complete response in rectal cancer has been studied in order to identify patients who would respond to neoadjuvant therapy and to individualize therapeutic strategies. Endoscopic ultrasound of the rectum is an accurate method for the evaluation of local tumor and lymph node invasion. Objective: To evaluate the potential of endoscopic ultrasound as a predictor of complete pathological response to neoadjuvant treatment in patients with locally advanced rectal cancer. Material and methods: Retrospective study of patients with rectal cancer from January 2014 to December 2016. Results: We obtained a statistical association between T stage by endoscopic ultrasound and complete pathological response (p = 0.015). It is not so for N, sphincter involvement, circumferential involvement and maximum tumor thickness (p = 0.723, p = 0.510, p = 0.233 and p = 0.114, respectively). When multivariate logistic regression analysis was applied to assess the degree of influence of the predictor variables on pathologic response, none of these variables was associated with complete pathologic response. Conclusion: Prediction of pathologic complete response in rectal cancer has been considered as the crucial point upon which treatments for rectal cancer could be individualized. So far, no imaging method has been able to demonstrate efficacy in predicting complete pathologic response, and in turn there is no direct association between any endosonographic finding that can accurately predict it.


Pathologic Complete Response; Rectal Cancer; Endoscopic Ultrasound

Full Text:



1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradio-therapy for rectal cancer. New England Journal of Medicine 2004; 351(17): 1731–1740.

2. Berardi R, Maccaroni E, Onofri A, et al. Locally advanced rectal cancer: The importance of a multidisciplinary approach. World Journal of Gastroenterology 2014; 20(46): 17279–17287.

3. Moaven J, Shami VM. Predicting pathologic response: The “bottom line” in the management of locally advanced rectal cancer. Gastrointestinal Endoscopy 2017; 85(3): 675–676.

4. Garland ML, Vather R, Bunkley N, et al. Clinical tumour size and nodal status predict pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. International Journal of Colorectal Disease 2014; 29(3): 301–307.

5. Smith JJ, Garcia-Aguilar J. Advances and challenges in treatment of locally advanced rectal cancer. Journal of Clinical Oncology 2015; 33(16): 1797–1808.

6. Ryan JE, Warrier SK, Lynch AC, et al. Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: A systematic review. Colorectal Disease 2016; 18: 234–246.

7. Russo AL, Ryan DP, Borger DR, et al. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. Journal of Gastrointestinal Cancer 2014; 45(1): 34–39.

8. Yoo BC, Yeo SG. Clinical utility of pretreatment prediction of chemoradiotherapy response in rectal cancer: A review. EPMA Journal 2017; 8(1): 61–67.

9. Perez RO. Predicting response to neoadjuvant treatment for rectal cancer: A step toward individualized medicine. Diseases of the Colon & Rectum 2011; 54(9): 1057–1058.

10. Habr-Gama A, Perez RO, São Julião GP, et al. Nonoperative approaches to rectal cancer: A critical evaluation. Seminars in Radiation Oncology 2011; 21(3): 234–239.

11. Qiu HZ, Wu B, Xiao Y, et al. Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. Colorectal Disease 2011; 13(12): 1353–1360.

12. Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemo radiotherapy for rectal cancer. Diseases of the Colon & Rectum 2013; 56(6): 698–703.

13. Cârţânå ET, Gheonea DI, Såoiu A. Advances in endoscopic ultrasound imaging of colorectal diseases. World Journal of Gastroenterology 2016; 22(5): 1756–1766.

14. Siddiqui AA, Fayiga Y, Huerta S. The role of endoscopic ultrasound in the evaluation of rectal cancer. International Seminars in Surgical Oncology 2006; 3(1): 36.

15. Marone P, de Bellis M, Avallone A, et al. Accuracy of endoscopic ultrasound in staging and restaging patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation. Clinics and Research in Hepatology and Gastroenterology 2011; 35(10): 666–670.

16. Vanagunas A, Lin DE, Stryker SJ. Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemo-radiation therapy. American Journal of Gastroenterology 2004; 99(1): 109–112.

17. de Jong EA, ten Berge JC, Dwarkasing RS, et al. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A meta-analysis. Surgery 2016; 159(3): 688–699.

18. Li N, Dou L, Zhang Y, et al. EUS of sequential endorectal US to predict the tumor response of preoperative chemoradiotherapy in rectal cancer. Gastrointestinal Endoscopy 2017; 85(3): 669–674.

19. Kim SH, Chang HJ, Kim DY, et al. What is the ideal tumor regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Cancer Research and Treatment 2016; 48(3): 998–1009.

20. Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemo radiotherapy for rectal cancer. British Journal of Surgery 2012; 99(7): 918–928.

21. Kawai K, Ishihara S, Nozawa H, et al. Prediction of pathological complete response using endoscopic findings and outcomes of patients who underwent watchful waiting after chemoradiotherapy for rectal cancer. Diseases of the Colon & Rectum 2017; 60(4): 368–375.

22. São Julião GP, Habr-Gama A, Vailati BB, et al. New strategies in rectal cancer. Surgical Clinics of North America 2017; 97(3): 587–604.

23. Pérez RO, Habr-Gama A, São Julião GP, et al. Should we give up the search for a clinically useful gene signature for the prediction of response of rectal cancer to neoadjuvant chemo-radiation? Diseases of the Colon & Rectum 2016; 59(9): 895–897.

24. Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: Are we getting closer to anal cancer management? Diseases of the Colon & Rectum 2013; 56(10): 1109–1117.

25. Heald RJ, Beets G, Carvalho C. Report from a consensus meeting: Response to chemoradiotherapy in rectal cancer-predictor of cure and a crucial new choice for the patient: On behalf of the Champalimaud 2014 Faculty for ‘Rectal cancer: When NOT to operate’. Colorectal Disease 2014; 16(5): 334–337.

DOI: https://doi.org/10.24294/irr.v5i1.1747


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License

This site is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.